María Salas1, Rubén Fernández-Santamaría2, Cristobalina Mayorga3, Esther Barrionuevo1, Adriana Ariza2, Teresa Posadas1, Jose Julio Laguna4, María Isabel Montañez5, Noemi Molina6, Tahia Diana Fernández2, María José Torres7. 1. Allergy Unit, IBIMA-Regional University Hospital of Malaga UMA, Málaga, Spain. 2. Research Unit for Allergic Diseases, IBIMA-Regional University Hospital of Malaga UMA, Málaga, Spain. 3. Allergy Unit, IBIMA-Regional University Hospital of Malaga UMA, Málaga, Spain; Research Unit for Allergic Diseases, IBIMA-Regional University Hospital of Malaga UMA, Málaga, Spain. 4. Allergy Unit, Cruz Roja Hospital, Madrid, Spain. 5. Research Unit for Allergic Diseases, IBIMA-Regional University Hospital of Malaga UMA, Málaga, Spain; Andalusian Center for Nanomedicine and Biotechnology, BIONAND, Málaga, Spain. 6. Andalusian Center for Nanomedicine and Biotechnology, BIONAND, Málaga, Spain; Department of Organic Chemistry, IBIMA, University of Malaga, Malaga, Spain. 7. Allergy Unit, IBIMA-Regional University Hospital of Malaga UMA, Málaga, Spain; Andalusian Center for Nanomedicine and Biotechnology, BIONAND, Málaga, Spain. Electronic address: mjtorresj@gmail.com.
Abstract
BACKGROUND: Reports of selective reactions to clavulanic acid (CLV) have increased in recent decades because of its increased prescription in combination with amoxicillin (AX) as AX-CLV. Basophil activation test (BAT) is used for diagnosing beta-lactam immediate hypersensitivity and is the only available in vitro assay for diagnosing patients with immediate hypersensitivity to CLV. However, few studies, and with limited numbers of patients have been published. OBJECTIVE: The aim of this study was to establish the sensitivity, specificity, and negativization rates of BAT to AX and CLV. METHODS: We studied 115 patients with immediate allergic reactions after AX-CLV treatment, 57 with selective reactions to AX (group A), 58 with selective reactions to CLV (group B), and 28 tolerant subjects. BAT was performed with AX in group A and with CLV in group B. A 4-year follow-up study was performed in patients with an initial positive BAT result. RESULTS: The overall sensitivity of BAT was 55%, specificity 89%, and positive predictive value (PPV) 96%. For group A, sensitivity was 47%, specificity 93%, and PPV 93%; for group B, sensitivity was 62%, specificity 89%, and PPV 92%. Follow-up study showed a faster negativization rate of BAT for group A, with around 40% of patients becoming negative at 12 months in both groups. CONCLUSIONS: The high PPV of BAT to CLV shows its potential value as a complementary tool to the allergological workup of patients with immediate allergic reactions after AX-CLV treatment. Importantly, the assay should be done within the first 12 months after the reaction to reduce false-negative results.
BACKGROUND: Reports of selective reactions to clavulanic acid (CLV) have increased in recent decades because of its increased prescription in combination with amoxicillin (AX) as AX-CLV. Basophil activation test (BAT) is used for diagnosing beta-lactam immediate hypersensitivity and is the only available in vitro assay for diagnosing patients with immediate hypersensitivity to CLV. However, few studies, and with limited numbers of patients have been published. OBJECTIVE: The aim of this study was to establish the sensitivity, specificity, and negativization rates of BAT to AX and CLV. METHODS: We studied 115 patients with immediate allergic reactions after AX-CLV treatment, 57 with selective reactions to AX (group A), 58 with selective reactions to CLV (group B), and 28 tolerant subjects. BAT was performed with AX in group A and with CLV in group B. A 4-year follow-up study was performed in patients with an initial positive BAT result. RESULTS: The overall sensitivity of BAT was 55%, specificity 89%, and positive predictive value (PPV) 96%. For group A, sensitivity was 47%, specificity 93%, and PPV 93%; for group B, sensitivity was 62%, specificity 89%, and PPV 92%. Follow-up study showed a faster negativization rate of BAT for group A, with around 40% of patients becoming negative at 12 months in both groups. CONCLUSIONS: The high PPV of BAT to CLV shows its potential value as a complementary tool to the allergological workup of patients with immediate allergic reactions after AX-CLV treatment. Importantly, the assay should be done within the first 12 months after the reaction to reduce false-negative results.
Authors: Jitesh Chauhan; Alex J McCraw; Mano Nakamura; Gabriel Osborn; Heng Sheng Sow; Vivienne F Cox; Chara Stavraka; Debra H Josephs; James F Spicer; Sophia N Karagiannis; Heather J Bax Journal: Antibodies (Basel) Date: 2020-10-16
Authors: Ángela Martín-Serrano; Juan M Gonzalez-Morena; Nekane Barbero; Adriana Ariza; Francisco J Sánchez Gómez; Ezequiel Pérez-Inestrosa; Dolores Pérez-Sala; Maria J Torres; María I Montañez Journal: Front Pharmacol Date: 2020-11-18 Impact factor: 5.810
Authors: Jitesh Chauhan; Chara Stavraka; Melanie Grandits; Lais C G F Palhares; Debra H Josephs; Katie E Lacy; James Spicer; Heather J Bax; Sophia N Karagiannis Journal: Cells Date: 2022-01-27 Impact factor: 7.666
Authors: Inmaculada Doña; Marina Labella; Gádor Bogas; Rocío Sáenz de Santa María; María Salas; Adriana Ariza; María José Torres Journal: Antibiotics (Basel) Date: 2022-08-03
Authors: Heimo Breiteneder; Zuzana Diamant; Thomas Eiwegger; Wytske J Fokkens; Claudia Traidl-Hoffmann; Kari Nadeau; Robyn E O'Hehir; Liam O'Mahony; Oliver Pfaar; Maria J Torres; De Yun Wang; Luo Zhang; Cezmi A Akdis Journal: Allergy Date: 2019-06-04 Impact factor: 13.146
Authors: Heather J Bax; Jitesh Chauhan; Chara Stavraka; Atousa Khiabany; Mano Nakamura; Giulia Pellizzari; Kristina M Ilieva; Sara Lombardi; Hannah J Gould; Christopher J Corrigan; Stephen J Till; Sidath Katugampola; Paul S Jones; Claire Barton; Anna Winship; Sharmistha Ghosh; Ana Montes; Debra H Josephs; James F Spicer; Sophia N Karagiannis Journal: Cells Date: 2020-07-07 Impact factor: 6.600